Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes. 

 -  2018 
<br/><br/> Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.  Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.  Materials & methods: The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.  Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2056-5623 
<br/><br/><label>Standard No.: </label>10.4155/fsoa-2017-0087 [doi] PMC5729603 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>IN PROCESS -- NOT YET INDEXED
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Medicine/Endocrinology<br/>Pathology<br/>Surgery/Endocrine Surgery<br/>Surgery/General Surgery
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article